Bris­tol My­er­s' Op­di­vo leads the pack with FDA ap­proval for re­sect­ed esophageal or GEJ can­cer

In a first for im­munother­a­pies, Bris­tol My­ers Squibb’s PD-1 block­buster Op­di­vo (nivolum­ab) won an­oth­er FDA ap­proval on Thurs­day, this time for the ad­ju­vant treat­ment of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER